{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015494","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.090671+00:00","generated_at":"2026-06-15T21:41:44.788636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"X4 Pharma Q1 net loss $24M; cash $94.4M funds ops into Q2 2024; WHIM NDA on track","bullets":["Cash, cash equivalents, and restricted cash of $94.4M as of March 31, 2023, sufficient into Q2 2024.","R&D expenses $22.1M (up from $14.1M YoY) including $5.0M accrual for probable in-licensing milestone.","Net loss $24.0M vs $22.0M YoY; includes $1.6M stock compensation and $5.4M gain on warrant liability.","U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half 2023.","Phase 2 chronic neutropenia data and regulatory path update anticipated in Q2/Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015494","json":"https://secwatch.observer/filing/0001628280-23-015494.json","markdown":"https://secwatch.observer/filing/0001628280-23-015494.md","text":"https://secwatch.observer/filing/0001628280-23-015494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/0001628280-23-015494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/xfor-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:41:44.788636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e5ac0c8f6f2aead5c910975be53ac48db60dc4e","claim":"X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"X4 Pharmaceuticals Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023015494/0001628280-23-015494-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}